GRI Bio (GRI) Expected to Announce Quarterly Earnings on Friday

GRI Bio (NASDAQ:GRI) will likely be releasing its results before the market opens on Friday, March 13th. Analysts expect GRI Bio to post earnings of ($29.27) per share for the quarter.

GRI Bio (NASDAQ:GRI) last issued its quarterly earnings results on Friday, January 30th. The company reported $23.52 earnings per share for the quarter. On average, analysts expect GRI Bio to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

GRI Bio Price Performance

Shares of GRI Bio stock opened at $2.94 on Thursday. The firm has a market cap of $4.26 million, a price-to-earnings ratio of -0.01 and a beta of -1.38. The stock’s 50-day moving average is $4.16 and its 200 day moving average is $30.30. GRI Bio has a one year low of $2.10 and a one year high of $311.36.

Analyst Ratings Changes

A number of equities analysts have issued reports on GRI shares. Weiss Ratings restated a “sell (e+)” rating on shares of GRI Bio in a report on Thursday, January 22nd. Ascendiant Capital Markets boosted their target price on shares of GRI Bio from $980.00 to $1,008.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Finally, Wall Street Zen lowered shares of GRI Bio to a “strong sell” rating in a research note on Saturday, January 31st. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $644.00.

GRI Bio Company Profile

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.